{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Rx
(2017)
Source:
BLA761053
(2017)
Source URL:
First approved in 2017
Source:
BLA761053
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA761033
(2016)
Source URL:
First approved in 2016
Source:
BLA761033
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA761034
(2016)
Source URL:
First approved in 2016
Source:
BLA761034
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA125521
(2016)
Source URL:
First approved in 2016
Source:
BLA125521
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA125509
(2016)
Source URL:
First approved in 2016
Source:
BLA125509
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA761038
(2016)
Source URL:
First approved in 2016
Source:
BLA761038
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA761046
(2016)
Source URL:
First approved in 2016
Source:
BLA761046
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA208471
(2016)
Source URL:
First approved in 2016
Source:
BLA208471
Source URL:
Class:
PROTEIN
Conditions:
Lixisenatide (trade name Adlyxin) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Status:
US Approved Rx
(2015)
Source:
BLA125511
(2015)
Source URL:
First approved in 2015
Source:
BLA125511
Source URL:
Class:
PROTEIN
Parathyroid hormone (PTH) is an 84-amino acid peptide that regulates the function of osteoblasts and osteocytes and is secreted by the parathyroid gland in response to changes in the concentration of extracellular calcium. Parathyroid hormone is approved under the brand name NATPARA as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. It is also available for treatment of postmenopausal osteoporosis in many European countries. Parathyroid hormone is an activator of parathyroid hormone 2 receptor. In addition, was shown, that downregulation of Notch in osteoblasts and osteocytes may represent a mechanism contributing to the anabolic effects of parathyroid hormone in bone.
Status:
US Approved Rx
(2015)
Source:
BLA125516
(2015)
Source URL:
First approved in 2015
Source:
BLA125516
Source URL:
Class:
PROTEIN
